[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Weill Medical College of Cornell University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":597},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,146,0,25,[9,47,72,90,115,138,167,204,223,241,263,283,307,337,358,384,401,425,448,474,495,515,535,557,576],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100642930",false,"NCT07639606","Mobile Cognitive Behavioral Therapy in Early Stroke Recovery","Inclusion Criteria:\n\n* Age 18-79\n* Positive screen on the Hospital Anxiety and Depression Scale (HADS), either the HADSD (depression, score \\>= 8) and\u002For HADS-A (anxiety, score \\>= 8).\n* Stroke that occurred within 1 month prior to study initiation.\n* Capacity to provide consent as determined by the UCSD Brief Assessment for Capacity to Consent (UBACC)\n* Montreal Cognitive Assessment (MoCA) score greater than or equal to 18, indicating no more than mild cognitive difficulties\n* Ability to use iPhone or iPad independently or through the assistance of a caregiver (participants will use their own iPhone if they have one, otherwise they will be loaned an iPad by the study team)\n* Able to adhere to all study requirements and willingness to participate in the full study duration\n\nExclusion Criteria:\n\n* Aphasia or neglect that would interfere with use of the app, as determined through evaluation by speech-language pathology and occupational therapy conducted as part of standard clinical care\n* Non-fluency in English\n* History of a major neurologic disorder or of serious mental illness (bipolar or psychotic disorder, alcohol or substance use disorder as assessed through chart review)\n* Active suicidal ideation requiring a higher level of care\n* Severe depression and\u002For anxiety based on the initial evaluation and clinical judgment of the PI, which warrants a higher level of care and\u002For immediate referral to psychiatric services\n* Any other clinical or medical reason in the initial evaluation that suggests the study is not appropriate for the participant","ALL","18 Years","79 Years",{"count":19,"type":20},10,"ESTIMATED","INTERVENTIONAL",[23],"NA","This study aims to pilot \"Maya,\" a mobile cognitive behavioral therapy app, for use in adults with stroke experiencing depression and\u002For anxiety. This study will assess the acceptability, feasibility, and preliminary efficacy of Maya within the acute rehabilitation period.",[26,27,28],"Anxiety","Stroke","Depression - Major Depressive Disorder",[30,31,32,33],"stroke recovery","stroke rehabilitation","cognitive behavioral therapy","CBT","NOT_YET_RECRUITING","2026-06-26",{"date":37,"type":38},"2026-06-30","ACTUAL",{"date":40,"type":20},"2026-07",{"date":42,"type":20},"2029-03",{"name":44,"class":45},"Weill Medical College of Cornell University","OTHER",1,{"id":48,"slug":4,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":46},"100645335","NCT07680140","Biomarker-Guided Antidepressant Selection","Biomarker-Guided Antidepressant Selection for Treatment-Resistant Depression","BioSelect","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Adults of all genders aged 18-70 at the time of screening\n3. Diagnosis of Major Depressive Disorder (by DSM-5 criteria)\n4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \\>= 14 or as determined by a study clinician)\n5. Failed at least 1 prior trial of standard first-line treatment for MDD per the modified Antidepressant Treatment History form, the Maudsley Staging Method, and APA Practice Guidelines (e.g., SSRI, SNRI, CBT) OR initiated and discontinued a trial of a first-line treatment for MDD (e.g. could not tolerate side effects, etc.)\n6. Not currently taking antidepressants OR on a stable dose of antidepressant for at least 1month prior to screening and plans to remain off antidepressants OR on this stable dose for the duration of participation\n7. Current medication regimen is compatible with safe participation in the trial in the assessment of a study clinician\n8. Access to psychiatric care before, during, and after completion of the study\n9. For females of reproductive potential: agreement to use effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation\n10. Proficiency in English sufficient to complete assessments and follow study procedure instructions\n11. Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n1. Imminent risk of suicide\n2. Presence of primary psychiatric diagnosis other than MDD (e.g., post-traumatic stress disorder, obsessive-compulsive disorder, MDD with psychotic features, primary psychotic illness, bipolar I or II disorder)\n3. History of epilepsy or a history of seizures that would influence the participant's risk for TMS-evoked seizures; history of any condition \u002F concurrent medication that could notably lower seizure threshold in the estimation of a study clinician\n4. Met criteria for any clinically significant substance use disorder (by DSM-V criteria) with active substance misuse in the 6 months prior to screening\n5. Lifetime history of PCP\u002Fketamine abuse\n6. History or presence of significant neurological disorder that may be contributing to current depressive symptoms in the judgment of a study clinician (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy)\n7. Presence of medical contraindications to ketamine, including liver function tests \\> 2.5x normal limit, recent myocardial infarction, congestive heart failure \\> stage 2, angina pectoris, clinically significant bradycardia or tachycardia at the baseline assessment, or uncontrolled hypertension\n8. MRI contraindication, including presence of ferromagnetic foreign metal bodies or implants, implanted or conductive ferromagnetic objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), and ferromagnetic permanent make-up that may undergo heating in an MRI scanner\n9. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation\n10. Abnormal bloodwork that may be contributing to depressive symptoms in the estimation of a study clinician (e.g. indicators of clinically significant hypothyroidism, kidney failure, liver failure, etc.)\n11. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures","70 Years",{"count":56,"type":20},27,[58],"PHASE4","Depression is one of the leading causes of disability worldwide. Common treatments like antidepressant medications and talk therapy work well for some people, but many others do not improve, even after trying multiple treatments.\n\nThis study will investigate two alternative treatment options for people whose depression has not responded to standard treatments: repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, and ketamine, a fast-acting medication. It can be difficult to decide between these interventions in clinical practice, and selecting between them often comes down to patient preference and trial and error. This study is working to optimize the selection approach: using biological and behavioral markers to match each person to identify biomarkers that may predict response to rTMS or ketamine. Investigators believe that differences in how individuals respond to rTMS versus ketamine are partly explained by differences in how their brains are organized, and that these differences can be measured and used to guide intervention decisions. This is an early-stage pilot study designed to test whether this biomarker-based approach is practical and acceptable to patients. Investigators will evaluate how well a combination of brain imaging and clinical data can predict, at the individual level, who is likely to respond to rTMS versus ketamine. The ultimate goal is to develop a reliable, scalable tool that helps clinicians make faster and more informed intervention decisions, reducing the time people with treatment-resistant depression spend searching for an antidepressant that works.",[28,61,62,63,64],"Treatment-resistant Depression (TRD)","rTMS","Ketamine","fMRI","2026-06-25",{"date":67,"type":38},"2026-07-02",{"date":40,"type":20},{"date":70,"type":20},"2028-12",{"name":44,"class":45},{"id":73,"slug":4,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":85,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":46},"100645239","NCT07680153","Neuromodulation of Mood Switch Circuitry in Bipolar Disorder","CircuitBD","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form.\n2. Adults of all genders aged 18-70 at the time of screening.\n3. Diagnosis of Bipolar Disorder (by DSM-V criteria)\n4. Depressive symptoms of at least moderate severity (GRID HDRS-17 score \\>= 14 or as determined by expert clinician).\n5. Not currently taking medications for BD OR on a stable dose of medication for at least 1 month prior to screening and plans to remain off medications OR on this stable dose for the duration of participation.\n6. Access to psychiatric care before, during, and after completion of the study.\n7. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation.\n8. Proficiency in English sufficient to complete assessments and follow study procedure instructions.\n9. Stated willingness to comply with all study procedures and availability for the duration of the study.\n\nExclusion Criteria:\n\n1. Imminent risk of suicide.\n2. Presence of a primary DSM-5 diagnosis other than bipolar disorder (BD-I or BD-II), or a current comorbid psychiatric disorder that, in the opinion of the investigators, would confound outcome assessment or interfere with safe participation.\n3. History of seizures or any condition \u002F concurrent medication that could notably lower seizure threshold.\n4. Met criteria for any significant substance use disorder (by DSM-V criteria) in the 6 months prior to screening.\n5. History or presence of significant neurological disorder (e.g., traumatic brain injury, stroke, Parkinson's disease or other movement disorder, epilepsy).\n6. History or presence of significant heart condition (e.g., recent myocardial infarction, congestive heart failure \\> stage 2, angina pectoris, bradycardia or tachycardia at the baseline assessment, uncontrolled hypertension).\n7. MRI contraindication, including presence of foreign metal bodies or implants, implanted or conductive objects in or near the head (e.g., stents, deep brain stimulators, vagus nerve stimulators, aneurysm coils, ocular implants, cochlear implants), permanent make-up.\n8. Individuals who are nursing, pregnant, or contemplating pregnancy within the length of study participation.\n9. Abnormal bloodwork for electrolytes, thyroid, or liver function.\n10. History or presence of any disorder or medical condition that, in the opinion of the study team, may compromise, interfere, or limit the individual's ability to complete the intervention or study procedures.",{"count":79,"type":20},62,[58],"This study is exploring a new approach to treating depression in people with bipolar disorder (BD). Investigators are testing whether a non-invasive form of brain stimulation can help us understand depressed-to-euthymic mood shifts and their related brain circuits in BD.\n\nInvestigators in this study will use a technique called repetitive transcranial magnetic stimulation, or rTMS. It uses non-invasive magnetic pulses delivered to the scalp to stimulate specific areas of the brain. rTMS is already used to treat depression, and investigators are now studying whether it can be made even more effective for people with bipolar disorder by precisely targeting an individualized brain region for each participant. Participants in this study will receive two courses of rTMS, one active and one placebo (called \"sham\"), in a randomized order so investigators can directly compare the effects. Before treatment, investigators will use brain scans (MRI) to create a personalized map of each participant's brain activity. This lets investigators identify the exact stimulation target most likely to influence the brain circuits involved in BD mood shifts. Investigators will track mood symptoms closely throughout the study to measure what changes.\n\nInvestigators believe that depression in BD is partly driven by disrupted communication between two brain regions involved in processing what feels important or rewarding. Investigators want to find out whether rTMS can restore that communication and whether doing so leads to measurable improvements in depression.",[83,84,62,64],"Bipolar Disorder (BD)","Bipolar 1 Depression",{"date":67,"type":38},{"date":40,"type":20},{"date":88,"type":20},"2031-12",{"name":44,"class":45},{"id":91,"slug":4,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":21,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":46},"100641208","NCT07661966","Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade","A Pilot Trial of Bright Light Therapy in Patients Receiving First Line Immune Checkpoint Blockade","IIT BLT","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Histologically confirmed diagnosis of advanced, unresectable melanoma or NSCLC.\n3. Presence of measurable tumor burden.\n4. Scheduled to receive first-line cancer-directed therapy with an immune checkpoint blockade-containing regimen, as monotherapy or combination (e.g. pembrolizumab, ipilimumab + nivolumab, ICB + chemotherapy).\n5. ECOG performance status 0-2.\n6. Able to provide informed consent.\n7. Access to reliable internet connection via WiFi or personal hotspot\n\nExclusion Criteria:\n\n1. Previous exposure to immune checkpoint blockade.\n2. Pregnant or breastfeeding.\n3. Use of melatonin or pharmacologic sleep aids (e.g., zolpidem, trazodone, benzodiazepines) within 14 days prior to enrollment.\n4. Diagnosis of bipolar disorder or history of mania or hypomania.\n5. Active psychosis, suicidal ideation, or recent psychiatric hospitalization (\\\u003C3 months).\n6. Poorly controlled seizures.\n7. Chronotype classified as extremely early or extremely late, based on the Munich Chronotype Questionnaire (MSFsc \\\u003C 2:00 or \\> 5:00).\n8. Night shift work within the past 30 days or expected during the intervention.\n9. Travel across ≥2 time zones within the past 14 days.\n10. Diagnosed or suspected untreated moderate to severe obstructive sleep apnea.\n11. Migraine with photophobia.\n12. Presence of ocular or photosensitivity conditions affecting vision (i.e. advanced bilateral cataracts not yet operated, advanced glaucoma with substantial visual field loss, optic nerve disease, ocular surgery within the past 3 months with unresolved visual symptoms, color blindness).",{"count":98,"type":20},12,[23],"This study is being done to test whether bright light therapy can be used to synchronize patients' circadian rhythms and allow ICB (immune-checkpoint blockade) therapy to be administered at a time in the circadian rhythm that optimizes clinical outcomes. This trial will test the feasibility of delivering bright light therapy (BLT) to patients undergoing ICB therapy.\n\nThis trial asks participants to spend 60 minutes every morning receiving daily bright light therapy for at least 7 days prior to starting Immune Checkpoint blockade-containing regimens (e.g. anti-PD-1 and\u002For anti-CTLA-4 alone or in combination with chemotherapy). The bright light therapy will be delivered via the Circadian OS iPad application.\n\nThere is evidence that a person's circadian rhythm can affect the response to immunotherapy. The circadian rhythm is a natural, internal process that regulates the sleep-wake cycle. Many patients with cancer have disrupted circadian rhythms and it's possible that disrupted circadian rhythms decrease the likelihood of responding to immunotherapy.\n\nThe idea is to use bright light therapy, delivered via the Circadian OS iPad application, for an hour in the morning to synchronize your circadian rhythm for a week before your planned immunotherapy. The investigators hope that this will increase the likelihood of a response to immunotherapy, however in this study, the investigators are mainly concerned with whether the bright light therapy is tolerable to patients.",[102,103],"Melanoma (Skin Cancer)","NSCLC (Non-small Cell Lung Cancer)",[95,105,106,107],"Bright Light Therapy","Circadian","Circadian Rhythm","2026-06-23",{"date":35,"type":38},{"date":111,"type":20},"2026-06",{"date":113,"type":20},"2027-12",{"name":44,"class":45},{"id":116,"slug":4,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":132,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":46},"100549384","NCT06433310","Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study","Inclusion Criteria:\n\n* Male or female adults over the age of 18 years\n\nExclusion Criteria:\n\n* History of a diagnosis of any gastrointestinal condition, such as inflammatory bowel syndrome or disease\n* Antibiotic usage within the past two weeks\n* Antifungal usage within the past month\n* Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU)\n* Adults taking medications known to interact with L-phenylalanine supplements, such as Monoamine Oxidase Inhibitors (MOAI), L-DOPA, and some antipsychotic drugs (complete and extensive drug list will be provided to interested participants during screening)\n* Pregnant or nursing women",true,{"count":122,"type":20},20,[58],"The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.",[126,127,128,129,130],"Gut Microbiome","Gut Health","Dietary Supplement","L-Phenylalanine","Phenylpropionic Acid","RECRUITING",{"date":35,"type":38},{"date":134,"type":38},"2024-10-17",{"date":136,"type":20},"2027-12-31",{"name":44,"class":45},{"id":139,"slug":4,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":21,"phases":147,"briefSummary":148,"conditions":149,"keywords":154,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":163,"leadSponsor":165,"locationsCount":166},"100641445","NCT07635147","Decision Support Tool for Patients With Advanced Breast Cancer","Communicating Options for Advanced Breast Cancer Support and Treatment (COAST)","COAST","Inclusion Criteria:\n\n* Male or female 18 years and older\n* Diagnosis of Stage IV breast cancer\n* English, Spanish or Mandarin speaking\n\nExclusion Criteria:\n\n* Early breast cancer\n* Individuals speaking languages other than English, Spanish, or Mandarin as their primary language",{"count":146,"type":20},100,[23],"The goal of this pilot study is to understand and improve the shared decision-making process between people with advanced breast cancer and their providers regarding their care and treatment. As part of this study, the researchers will evaluate a decision support tool called COAST that was designed to support patients and providers in having meaningful conversations. The main questions it aims to answer are:\n\n1. Can the COAST tool improve the quality of communication between patients and their oncology providers?\n2. Is the COAST tool acceptable, appropriate, and easy to use at NYP-Weill Cornell Medicine, NYP-Brooklyn Methodist Hospital and NYP-Queens?\n\nParticipants will be asked to fill out two surveys: one before they use the COAST tool and another about 2 - 4 weeks later. Some patients will also be invited for an interview.",[150,151,152,153],"Breast Cancer Metastatic","Advanced Breast Cancer","Stage 4 Breast Cancer","Stage IV (Metastatic) Breast Cancer",[155,156,157,158],"Decision support tool","advanced breast cancer","communication","Treatment preferences","2026-06-18",{"date":161,"type":38},"2026-06-22",{"date":111,"type":20},{"date":164,"type":20},"2028-02",{"name":44,"class":45},3,{"id":168,"slug":4,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":21,"phases":175,"briefSummary":176,"conditions":177,"keywords":182,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":198,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":46},"100527171","NCT06144294","Whole-Body Hyperthermia for Mood and Anxiety Disorders","Inclusion Criteria\n\n* Group 2\n\n  * Arm 1: Healthy women or transgender men 18-50 years of age, ≤ 6 months postpartum\n  * Arm 2: Women and transgender men 18-50 years of age, ≤ 6 months postpartum, meeting criteria for a major depressive episode in the postpartum period on the MINI.\n  * Arm 3: Healthy adults of both sexes 18-50 years of age.\n  * Arm 4: Adults of both sexes 18-50 years of age meeting criteria for an episode of major depression or generalized anxiety disorder on the Mini International Neuropsychiatric Interview (MINI)\n* Group 2: Sub-study\n\n  * Subjects enrolled in Group 2 are eligible for an optional additional sub-study (Group 2: Sub-study); inclusion criteria are the same as for Group 2.\n\nExclusion criteria for all:\n\n* For logistics, we will exclude individuals with BMI \\>30 and waist size \\> 35, who may not fit comfortably in the sauna dome for all cohorts described above.\n* For contraindications to hyperthermia, we will exclude from all cohorts listed above, individuals with severe cardiovascular disease, including congestive heart failure, coronary artery disease, uncontrolled hypertension, and hypotension; pregnancy; active substance use disorders; recent major injuries or surgeries (\\\u003C1 week prior); impaired sweating (those with multiple sclerosis, diabetes mellitus with neuropathy, central nervous system disease, heat insensitivity); a history or family history of malignant hyperthermia, fever or active signs of infection; taking medications that may have interactions with hyperthermia (for example, barbiturates, diuretics, and beta blockers) and the use of an antipyretic or anihistamine medication in the 12 hours prior to the WBH intervention. Individuals with above mentioned conditions will be excluded since either WBH might deteriorate their conditions or it is unknown how their condition will be affected by WBH.\n* For contraindications to immune analyses, we will exclude individuals with conditions that might affect immune analyses, including individuals with known active autoimmune or endocrine disease and individuals with active infection at baseline.\n\nAdditional exclusion criteria by cohort or applicable study group:\n\n* Group 2\n\n  * Arm 1: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 2: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n  * Arm 3: For psychiatric contraindications, we will exclude individuals with a history of psychiatric disorders as assessed by MINI since the cohort will consist of mentally healthy individuals as a control group.\n  * Arm 4: For psychiatric contraindications, we will exclude individuals with bipolar disorder or other Axis I psychiatric disorders except depressive and anxiety disorders and individuals taking antidepressants who are unwilling to hold antidepressant dose steady from recruitment through study termination. In this cohort we exclude individuals with other psychiatric disorders except depressive and anxiety disorders to rule out the effect of other psychiatric diseases on the outcome.\n* Group 2 and Group 2: Sub-study - All participants\n\n  * For contraindications to use of the e-Celsius capsule that will be used to measure core temperature, we will exclude individuals with pacemakers or any other electric medical implant, individuals with a current intestinal disorder that could lead to obstruction of the digestive tract including gastroparesis, individuals with history of diverticula, individuals with history of past surgical procedures in the gastrointestinal tract, individuals with a swallowing disorder and individuals with Crohn's disease.\n* Study Group 3 - All participants\n\n  * For contraindications to MRI, individuals with metal in the body will be excluded from participating in the MRI portion of the research since magnetic fields in MRI scanners can cause dangerous interactions in patients with metallic foreign bodies: projectile effect, twisting, burning, artifacts, and device malfunction (interference with a pacemaker).","50 Years",{"count":174,"type":20},240,[23],"This study aims to examine the scientific mechanisms of whole-body hyperthermia (WBH), a novel, rapidly acting, single session antidepressant and anxiolytic therapy. It also aims to determine its feasibility and acceptability in women with postpartum depression (PPD). The study will enroll four cohorts of participants: healthy postpartum controls; postpartum women with PPD; healthy adult controls; and adults with major depressive disorder or anxiety disorders in a longitudinal protocol.",[178,179,180,181],"Postpartum Depression","Mood Disorders","Anxiety Disorders","Postpartum Anxiety",[183,184,185,186,187,188,189,190,191,192,193,194,195,196,197,64],"postpartum depression","mood disorders","anxiety disorders","postpartum anxiety","whole-body hyperthermia","antidepressant therapy","anxiolytic therapy","postpartum feasibility and acceptability","psychoneuroimmunology","Broad-band neural suppression","EEG","Likert scale","inflammatory activity","pro-inflammatory cytokines","precision functional brain maps",{"date":108,"type":38},{"date":200,"type":20},"2028-06",{"date":202,"type":20},"2032-12",{"name":44,"class":45},{"id":205,"slug":4,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":21,"phases":212,"briefSummary":213,"conditions":214,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":217,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":221,"locationsCount":222},"100482495","NCT05562778","Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment","Evaluation of a Chatbot to Maximize Hereditary Cancer Genetic Risk Assessment in an Underserved Gynecology Population","Inclusion Criteria:\n\n* 8 years of age or older.\n* Scheduled for a New Patient appointment in the gynecology clinic. Speaks and reads in English.\n* Access to a telephone with texting capacity.\n* Has not had prior genetic testing for hereditary cancer syndromes.\n\nExclusion Criteria:\n\n* Under 18 years of age\n* Has had previous genetic testing for hereditary cancer syndromes\n* Does not read\u002Fspeak in English\n* Does not have access to a phone with texting capabilities",{"count":211,"type":20},150,[23],"In this study, the investigators aim to compare a mobile health platform, known as a 'chatbot,' that leverages artificial intelligence and natural language processing to scale communication, to 'usual care' that patients would receive. This comparison will enable the investigators to determine if the chatbot system can improve rates of recommendation for genetic testing among patients at elevated risk of harboring a familial cancer syndrome in an all-Medicaid gynecology clinic. Furthermore, the investigators aim to evaluate facilitators of inequity in regard to patient access to and utilization of genetic testing services.",[215,216],"Gynecologic Cancer","Hereditary Cancer Syndrome",{"date":108,"type":38},{"date":219,"type":38},"2023-01-15",{"date":113,"type":20},{"name":44,"class":45},4,{"id":224,"slug":4,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":54,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":229,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":240,"locationsCount":46},"100302515","NCT03218137","Use of Adenosine to Determine the Electrophysiological Mechanism of Premature Ventricular Contractions","Inclusion Criteria:\n\n* Diagnosis of premature ventricular contractions (PVCs)\n* Scheduled to undergo an electrophysiology study with the intention of performing cardiac ablation for the treatment of PVCs\n* Male or female between the ages of 18 and 70 years\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* Any structural heart disease\n* Coronary artery disease (≥ 70% stenosis)\n* Current treatment with anti-arrhythmic drugs\n* Pregnant\n* Asthma (if administering adenosine)",{"count":146,"type":20},[58],"Unblinded, controlled, non-randomized, mechanistic study to determine whether physiological mechanisms underlying PVC are sensitive to adenosine. One hundred subjects undergoing clinically-indicated, standard-of-care cardiac electrophysiology study (EPS) procedure for PVCs will receive adenosine and\u002For verapamil to learn if their arrhythmias are inducible similarly to sustained ventricular tachycardia.",[232],"Premature Ventricular Contraction (PVC)",[234,235],"Subjects","diagnosed",{"date":108,"type":38},{"date":238,"type":38},"2017-02-13",{"date":136,"type":20},{"name":44,"class":45},{"id":242,"slug":4,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":244,"acronym":4,"eligibilityCriteria":245,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":246,"targetDuration":4,"studyType":21,"phases":248,"briefSummary":249,"conditions":250,"keywords":252,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":261,"locationsCount":262},"100501942","NCT05815810","Novel Delivery Method of Transgender Voice Modification Training Using a Mobile Application","Inclusion Criteria:\n\n* Identify as a transgender individual\n* Be 18 years or older\n* Be able to read and write in English\n* Have an iOS or Android Device\n\nExclusion Criteria:\n\n* Identify as cisgender\n* Experience hoarseness\n* Experiencing any physical pain related to voice use",{"count":247,"type":20},50,[23],"The investigators hypothesize that the mobile application they developed for transgender and gender diverse individuals (TGGD) will be equivalent or better than traditional speech therapy in improving voice quality. The investigators will measure both how the participants feel about their voices and how their voice actually sounds to see if the app is effective.",[251],"Transitioning Voice of Transgender and Gender Diverse People",[253,254,255],"Transgender","Voice therapy","Mobile Application","2026-06-17",{"date":161,"type":38},{"date":259,"type":20},"2026-10",{"date":88,"type":20},{"name":44,"class":45},2,{"id":264,"slug":4,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":268,"minAge":16,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":21,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":46},"100430932","NCT04891510","A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery","Inclusion Criteria:\n\n* Female;\n* Documented history of previous breast surgery (either complete or partial mastectomy);\n* Available harvest sites for fat grafting as documented by plastic surgeon;\n* BMI \\> 20;\n* Anticipated harvested fat volume \\> 50cc;\n* Competency and willingness to provide consent\n\nExclusion Criteria:\n\n* Suspected or known to be pregnant","FEMALE",{"count":270,"type":20},135,[23],"The purpose of this study is to learn whether there is a superior fat processing method in terms of graft retention in breast reconstruction after mastectomy.",[274,275,276],"Mastectomy","Mammaplasty","Breast Reconstruction",{"date":161,"type":38},{"date":279,"type":38},"2021-05-19",{"date":281,"type":20},"2028-06-01",{"name":44,"class":45},{"id":284,"slug":4,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":291,"briefSummary":292,"conditions":293,"keywords":296,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":301,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":46},"100410556","NCT04626050","General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to Occupational Trauma","A Brief Phased Two-Step Intervention for Treating General Psychological Distress, PTSD, and Co-Morbidities in Healthcare Workers Consequent to Occupational Trauma","Inclusion Criteria:\n\n* Any healthcare worker providing medical care or support who has experienced occupational-related trauma\n* English-speaking\n* Age \\>18\n* Medically stable\n* Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments\n* If on psychotropic medication stable for prior 60 days\n\nFor phase II additional inclusion criteria:\n\n\\- Current diagnosis of PTSD\n\nExclusion Criteria:\n\n* Current significant unstable medical illness precluding regular session attendance or assessment completion\n* Participants who in the investigator's judgment pose a current homicidal, suicidal, or other risk\n* Lifetime or current diagnosis of schizophrenia or other psychotic disorder\n* Participation in a clinical trial or concurrent evidence-based treatment for psychiatric conditions or PTSD during the previous 3 months.",{"count":290,"type":20},120,[23],"It is expected that large numbers of healthcare workers experience a broad range of psychological reactions and symptoms including anxiety, depression, moral distress, and trauma symptoms that will cause both significant suffering as well as occupational and social impairment. The purpose of this study is to find interventions which are helpful in treating psychological distress in healthcare workers adversely affected by occupational-related trauma.\n\nThere are two phases of the study. All participants will take part in Phase I, which consists of 4 sessions over a two-week period of either a narrative writing intervention or a medical music intervention. Participants will be randomly assigned to the narrative writing intervention or medical music intervention.\n\nAfter Phase I, participants will be re-assessed. Healthcare workers who meet criteria for PTSD will be given the option to participate in Phase II of the study, in which they will be offered a choice between one of two evidence-based treatments for PTSD: Interpersonal Therapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minute sessions scheduled twice weekly. Participants will be allowed to choose a preferred treatment in Phase II. After Phase II participants will complete a final assessment concluding the study. All interventions will be offered using distance technology.",[294,295],"Post-traumatic Stress Disorder","Moral Injury",[297,295,298,299,300],"PTSD","Psychological Distress","Healthcare Workers","Occupational Trauma",{"date":161,"type":38},{"date":303,"type":38},"2022-01-20",{"date":305,"type":20},"2028-04",{"name":44,"class":45},{"id":308,"slug":4,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":313,"enrollmentInfo":314,"targetDuration":4,"studyType":21,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":46},"100627384","NCT07447934","Trial to Test the Effectiveness of Vibrotactile Stimulation for Lower Limb Spasticity","Vibrotactile Stimulation for Lower Limb Spasticity","Inclusion Criteria:\n\n* ≥6 months following neurologic diagnosis leading to spasticity\n* Modified Ashworth Scale (MAS) score of 3 or lower on ankle plantar flexor.\n* Ability to stand (with or without assistance) and lie supine.\n* Able to understand and comply with study procedures.\n\nExclusion Criteria:\n\n* Uncontrolled systemic illness or serious medical conditions that could interfere with study procedures.\n* Previous surgery to treat spasticity in the affected lower limb.\n* Prior Botulinum Toxin (BoNT) therapy in the target limb within 4 months.\n* Unstable medication regimens for spasmolysis or muscle relaxation.\n* Participation in tone-related treatments (e.g., physiotherapy, TENS, acupuncture) within 4 weeks prior to baseline. If ongoing treatment started more than 4 weeks before baseline, it should remain consistent throughout the study","85 Years",{"count":7,"type":20},[23],"The goal of this clinical trial is to find out if Vibrotactile Stimulation (VTS) can help improve mobility and reduce spasticity (muscle stiffness) in people with lower limb spasticity. The study will also look at how VTS affects walking speed. The main questions it aims to answer are:\n\n* Which areas of the body are the best for applying VTS?\n* Does VTS help improve walking speed in people with lower limb spasticity?\n\nParticipants will:\n\n* Receive 15 minutes of VTS treatment on different parts of the body\n* Use the VTS device for 60 minutes during supervised lab sessions and at home (at rest and while walking)\n* Complete a daily log of how much time the device was used for and note any issues or difficulties the participant experience\n* Complete assessments after the treatment to measure change in mobility\n* Complete surveys about how comfortable the device is to use",[318],"Lower Limb Spasticity",[320,321,322,323,324,325,326,327,328,329],"mobility","lower limb","spasticity","walking endurance","home device","quality of life","vts","LLS","gait","stroke","2026-06-15",{"date":256,"type":38},{"date":333,"type":38},"2026-04-30",{"date":335,"type":20},"2027-10-31",{"name":44,"class":45},{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":15,"minAge":342,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":21,"phases":344,"briefSummary":345,"conditions":346,"keywords":348,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":330,"lastUpdatePostDateStruct":352,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":46},"100415119","NCT04685486","Virtual Reality for Pain Management in Burn Patients","Inclusion Criteria:\n\n* 8 years and older\n* Patients with a burn injury and is in the Burn Unit at New York Presbyterian\n* Awake, alert, ambulatory\n* The burn comprises less than 15% total body surface area (TBSA)\n* The patient does not require conscious sedation such as ketamine for staple removal or wound dressing changes\n* The patient is able to give informed consent\n\nExclusion Criteria:\n\n* Diagnosis of a cognitive disorder, psychotic disorder or bipolar I as determined by self-report from previous diagnosis\n* Current opioid abuse","8 Years",{"count":247,"type":20},[23],"This study is a randomized proof-of-concept study to assess the efficacy of Virtual Reality (VR) vs standard of care in 50 adult patients in the New York Presbyterian Burn Unit. The participants who are randomized to receive the virtual reality intervention will also receive opioids, which is the standard of care and is known to be effective. Participants will be randomly assigned to two groups. The first group will receive VR during their painful procedure (e.g., wound dressing changes, physical therapy etc.) in addition to the standard of care. The other group will receive standard of care (and no VR).",[347],"Pain",[349,350,26,351],"Virtual Reality","Pain Management","Depression",{"date":256,"type":38},{"date":354,"type":38},"2018-06-01",{"date":356,"type":20},"2027-05",{"name":44,"class":45},{"id":359,"slug":4,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":364,"enrollmentInfo":365,"targetDuration":4,"studyType":21,"phases":367,"briefSummary":368,"conditions":369,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":46},"100560656","NCT06579989","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures","Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures: A Pilot Study","Inclusion Criteria:\n\n* US-Guided Injection for Neurogenic Cough:\n\n  1. Age over 18 years\n  2. Recommended to undergo superior laryngeal nerve block\n* US-Assessment of Superior Laryngeal Nerve Anatomy\n\n  1. Age over 18 years\n  2. No cough complaints\n* US-Assessment of Injectate Volume:\n\n  1. Documentation of unilateral vocal fold paresis\u002Fparalysis or atrophy\n  2. Age over 18 years\n  3. Recommended to undergo injection laryngoplasty\n* US-Assessment of Swallow:\n\n  1. Age over 18 years\n  2. Presents with swallowing complaints\n* US-Assessment of Normal Swallow:\n\n  1. Age over 18 years\n  2. Presents without swallowing complaints\n* US-Assessment of Voice:\n\n  1. Age over 18 years\n  2. Undergoing evaluation of voice problems\n\nExclusion Criteria:\n\n1. Age under 18 years and over 99 years\n2. Open neck wound including tracheostomy","99 Years",{"count":366,"type":20},200,[23],"Investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. Participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.",[370,371,372,373,374,375],"Cough","Vocal Cord Atrophy","Vocal Cord Paresis","Vocal Cord Paralysis","Dysphagia","Dysphonia","2026-06-12",{"date":378,"type":38},"2026-06-16",{"date":380,"type":20},"2027-01",{"date":382,"type":20},"2030-01",{"name":44,"class":45},{"id":385,"slug":4,"hasResults":11,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":120,"sex":15,"minAge":16,"maxAge":390,"enrollmentInfo":391,"targetDuration":4,"studyType":21,"phases":392,"briefSummary":393,"conditions":394,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":396,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":400,"locationsCount":46},"100476108","NCT05479643","A Personalized Voice Restoration Device for Patients With Laryngectomy","A Pilot Study for a Novel and Personalized Voice Restoration Device for Patients With Laryngectomy","Inclusion Criteria:\n\nGroup A: Healthy Volunteers\n\n1. Adult subjects, 18 or older\n2. Without any voice impairments\n\nGroup B: Subjects with Aphonia or Dysphonia\n\n1. Adult subjects, 18 or older\n2. Documentation of severe dysphonia and\u002For aphonia, or a GRBAS score \\> 0 (GRBAS is a scale that can be used to assess voice quality of subjects who do not have a recorded history of dysphonia or aphonia. The GRBAS scale evaluates for grade, roughness, breathiness, asthenia, and strain).\n\nExclusion Criteria:\n\n\\- Group A: Healthy Volunteers\n\n1\\. Voice impairment\n\nGroup B: Subjects with Aphonia or Dysphonia\n\n1\\. Subjects whose face muscles are entirely paralyzed","110 Years",{"count":146,"type":20},[23],"The investigators will conduct a pilot experiment for a novel and personalized method for voice restoration using machine learning applied to surface EMG (sEMG) signal from articulatory muscles of the face and the neck allowing recognition of silent speech. The investigators predict that the use novel personalized method for voice restoration will be feasible and successful for patients.",[375,395],"Aphonia",{"date":378,"type":38},{"date":398,"type":20},"2027-12-01",{"date":88,"type":20},{"name":44,"class":45},{"id":402,"slug":4,"hasResults":11,"nctId":403,"briefTitle":404,"officialTitle":405,"acronym":4,"eligibilityCriteria":406,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":407,"targetDuration":4,"studyType":21,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":46},"100610243","NCT07225049","Integrated PTSD and Chronic Pain Treatment","Pilot of an Integrated Treatment for Comorbid PTSD and Chronic Pain","Inclusion Criteria:\n\n* 18 years or older\n* English-speaking\n* Currently meets criteria for PTSD, assessed by the CAPS-5 (any trauma type) - Chronic pain, assessed by greater than or equal to 4 on a scale of 0-10 pain severity over the past 3 months\n* Medically stable at the time of study enrollment (chronic illness and disability does not prevent attendance of outpatient therapy sessions)\n* Stable on psychotropic medication for past 60 days\n* Agreed to not change current medication or pain-related treatments over the course of the study unless medically necessary\n* Must be located in the state of New York for virtual assessments and treatment sessions\n\nExclusion Criteria:\n\n* Lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar I disorder\n* Participation in concurrent evidence-based psychological treatment for PTSD or chronic pain during the past 3 months\n* Participants must not participate in an evidence-based psychological treatment for either PTSD or pain during the course of the study.\n* Moderate or severe substance use in the past 90 days\n* Cognitive impairment to the degree that the patient cannot provide informed consent or fill out assessment measures\n* Participants who in the PI's judgement pose a current homicidal or suicidal risk",{"count":122,"type":20},[23],"Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions. Gold standard treatments exist for both PTSD (e.g., Prolonged Exposure; PE) and chronic pain (e.g., Cognitive Behavioral Therapy for Chronic Pain; CBT-CP) and are generally offered sequentially (i.e., one at a time for the condition that is most prominent). Treating these conditions separately may overlook their interconnected nature, which may reduce efficacy and increase dropout. Thus, there is a need for an intervention to target both simultaneously, which may be more effective and efficient than treating conditions sequentially.\n\nThis is a single-arm pilot study to assess the feasibility and acceptability of an integrated treatment for adults with comorbid PTSD and chronic pain. The intervention consists of 12 90-minute virtual psychotherapy sessions scheduled twice per week. The treatment draws from modules in PE and CBT-CP including psychoeducation, exposure to feared\u002Favoided situations and activities, processing of exposures, behavioral activation, breathing and relaxation techniques, sleep hygiene, symptom monitoring, and structured homework assignments. Baseline and post-treatment assessments will be conducted.",[297,411],"Chronic Pain",[297,411,413,414,415,416,417],"Integrated Treatment","Comorbidity","Prolonged Exposure","CBT for Chronic Pain","Cognitive Behavioral Therapy for Chronic Pain","2026-06-11",{"date":330,"type":38},{"date":421,"type":38},"2025-12-08",{"date":423,"type":20},"2027-08",{"name":44,"class":45},{"id":426,"slug":4,"hasResults":11,"nctId":427,"briefTitle":428,"officialTitle":429,"acronym":4,"eligibilityCriteria":430,"healthyVolunteers":11,"sex":268,"minAge":16,"maxAge":4,"enrollmentInfo":431,"targetDuration":4,"studyType":21,"phases":433,"briefSummary":434,"conditions":435,"keywords":437,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":442,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":166},"100595442","NCT07032506","Intrauterine Stent Placement Following Hysteroscopic Septum Resection","A Randomized Controlled Trial of Intrauterine Stent Placement Following Hysteroscopic Septum Resection","Inclusion Criteria:\n\n* Age 18 and above\n* Patients electing to undergo hysteroscopic septoplasty following an informed consent and shared decision making process\n* Uterine septum of at least 50% of the uterine cavity length as quantified on 3-dimensional saline infusion ultrasound\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent\n* History of prior uterine septum resection\n* History of prior transmural uterine surgery\n* Preexisting intrauterine adhesions or prior treatment for intrauterine adhesions\n* Individuals in whom complete septum resection is unable to be performed as a single procedure",{"count":432,"type":20},320,[23],"The study hopes to learn the best way to prevent internal scar tissue after septum removal. The use of an intrauterine foley catheter balloon may prevent the formation of adhesions following surgery.",[436],"Intrauterine Adhesion",[438,439,440,441],"intrauterine foley balloon catheter stent","uterine malformations","uterine septums","hysteroscopic septoplasty",{"date":376,"type":38},{"date":444,"type":38},"2026-05-14",{"date":446,"type":20},"2031-12-31",{"name":44,"class":45},{"id":449,"slug":4,"hasResults":11,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":453,"eligibilityCriteria":454,"healthyVolunteers":11,"sex":268,"minAge":4,"maxAge":4,"enrollmentInfo":455,"targetDuration":4,"studyType":21,"phases":457,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":468,"startDateStruct":469,"completionDateStruct":471,"leadSponsor":473,"locationsCount":166},"100589922","NCT06960707","Two Versus One Week Breast Radiotherapy (RT)","Prospective Randomized Trial of Two Versus One Week Accelerated Radiotherapy (PRATO)","PRATO","Inclusion Criteria:\n\n1. Women status post segmental mastectomy.\n2. If unilateral, pT1-2 breast cancer excised with negative margins.\n3. If bilateral, pT1-2 breast cancer excised with negative margins AND\u002FOR pTis excised with negative margins.\n4. Clinically N0 (cN0 as determined by ultrasound\u002FSOUND criteria) or pN0-1 or Nx or sentinel node negative.\n5. Ductal carcinoma in situ DCIS with negative margins (no DCIS on inked margins).\n6. Women with previous contralateral treated breast cancer can be enrolled in the trial.\n\nExclusion Criteria:\n\n1. Previous radiation therapy to the ipsilateral breast.\n2. \\>90 days from last surgery, unless s\u002Fp adjuvant chemotherapy.\n3. \\>60 days from last chemotherapy.\n4. Male breast cancer.\n5. Ongoing treatment for severe autoimmune disease.",{"count":456,"type":20},400,[458],"PHASE3","This study is comparing two different radiation therapy approaches for early breast cancer to see which one is better for patients. One group will receive radiation over one week (based on the FAST-FORWARD trial), and the other group will receive radiation over two weeks with an extra focused dose (called a \"concomitant boost\"). The study will look at how the treatments affect side effects, breast appearance, and cancer control in the breast. It also aims to find out if the two-week treatment does a better job at preventing cancer from coming back in the breast over the long term.",[461],"Breast Cancer",[463,464,465,466,467],"Accelerated Radiotherapy","Prone Position","Adjuvant Setting","Non-Inferiority","Concomitant Boost",{"date":330,"type":38},{"date":470,"type":38},"2025-04-29",{"date":472,"type":20},"2040-12-31",{"name":44,"class":45},{"id":475,"slug":4,"hasResults":11,"nctId":476,"briefTitle":477,"officialTitle":478,"acronym":4,"eligibilityCriteria":479,"healthyVolunteers":11,"sex":15,"minAge":480,"maxAge":481,"enrollmentInfo":482,"targetDuration":4,"studyType":21,"phases":484,"briefSummary":485,"conditions":486,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":489,"startDateStruct":490,"completionDateStruct":492,"leadSponsor":494,"locationsCount":222},"100561208","NCT06587165","Quantifying New Heart Muscle Cells","A Pilot Study for Quantifying New Heart Muscle Cells","Inclusion Criteria:\n\n* Patients at 30 days of age to 1 year of age undergoing scheduled elective cardiac surgery will be eligible for study inclusion.\n* The investigators will recruit patients at 30 days of age to 1 year of age with those types of heart disease whose surgical approach has a high probability of myocardial resection.\n* Diagnosis of ToF\u002FPS or other types of heart disease that have a high likelihood of requiring surgery that involves routine resection of myocardium that becomes available for research\n\nExclusion Criteria:\n\n* Patients with low chance of having resection of myocardium as part of their surgical care.","30 Days","1 Year",{"count":483,"type":20},30,[23],"Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration.\n\nThe study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.",[487,488],"Tetralogy of Fallot With Pulmonary Stenosis","Heart Failure",{"date":330,"type":38},{"date":491,"type":38},"2026-05-15",{"date":493,"type":20},"2027-03-01",{"name":44,"class":45},{"id":496,"slug":4,"hasResults":11,"nctId":497,"briefTitle":498,"officialTitle":498,"acronym":4,"eligibilityCriteria":499,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":500,"targetDuration":4,"studyType":21,"phases":502,"briefSummary":503,"conditions":504,"keywords":506,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":514,"locationsCount":46},"100514327","NCT05977049","Psychosocial Support for Patients With Takotsubo Syndrome","Inclusion Criteria:\n\n\\- All patients with documented diagnosis of Takotsubo Syndrome greater than 18 years old.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of Takotsubo Syndrome already undergoing Psychotherapy or those who choose not to participate.\n* Vulnerable populations such as prisoners, non-English speaking subjects, pregnant women, and subjects unable to provide written informed consent will not be included in this research.",{"count":501,"type":20},24,[23],"The study hypothesis is that participants enrolled in a virtual Takotsubo support group will have significantly less anxiety at one year.",[505],"Takotsubo Cardiomyopathy",[507,508,509],"Takotsubo","Cardiomyopathy","Takotsubo Syndrome",{"date":330,"type":38},{"date":512,"type":38},"2024-04-17",{"date":136,"type":20},{"name":44,"class":45},{"id":516,"slug":4,"hasResults":11,"nctId":517,"briefTitle":518,"officialTitle":519,"acronym":520,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":522,"enrollmentInfo":523,"targetDuration":4,"studyType":21,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":528,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":533,"locationsCount":534},"100511728","NCT05943210","The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer","The Radiation Oncology-Biology Integration Network (ROBIN) Molecular Characterization Trial (MCT) of Standard Short Course Radiotherapy for Rectal Cancer.","ROBIN","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of adenocarcinoma of the rectum\n* Age ≥ 18 years\n* ECOG performance status 0-1\n* cT2-T3N0 or cT1-3N1 or cT4 or cN2\n* Rectal cancer amenable to total mesorectal excision\n* No evidence of distant metastases\n* No prior pelvic radiation therapy\n* No prior chemotherapy or surgery for rectal cancer\n* Total neoadjuvant therapy (short course radiotherapy followed by consolidative chemotherapy) is allowed\n* No infections requiring systemic antibiotic treatment\n* Hgb \\>8.0 gm\u002FdL, PLT \\> 150,000\u002Fmm3, total bilirubin ≤ 1.5x upper limit of normal, AST ≤ upper limit of normal, ALT ≤ 3x upper limit of normal\n* Patients must read, agree to, and sign a statement of informed consent prior to participation in this study. Patients who do not read or understand English or eligible but must have the consent form read to them in its entirety by an official translator. Informed consent for non-literate or non-English speaking patients may not be obtained by using a relative or a member of the patient's clinical team as a translator.\n* Female participants or reproductive potential, defined as not surgically sterilized and between menarche and 1 year post menopause, must have a negative serum pregnancy test within 4 weeks prior to initiation of study treatment.\n* Women with childbearing potential who are negative for pregnancy (urine or blood) and who agree to use effective contraceptive methods. A woman of childbearing potential is defined by one who is biologically capable of becoming pregnant. Reliable contraception should be used from trial screening and must be continued throughout the study.\n\nExclusion Criteria:\n\n* Recurrent rectal cancer\n* Primary unresectable rectal cancer is defined as a primary rectal tumor which, on the basis of either physical exam or pelvic MRI, is deemed to be adherent or fixed to adjacent pelvic structures (en bloc resection will not be achieved with negative margins).\n* Patients who have received prior pelvic radiotherapy\n* Patients with prior allogenic stem cell or solid organ transplantation.\n* Patients receiving treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor-α agents) administered at \\>10 mg\u002Fday prednisone or equivalent within 2 weeks prior to initiation of study treatment.\n* Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment would make them inappropriate candidates for entry into this study\n* Patients receiving other anticancer or experimental therapy. No other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-VEGF\u002FFlk-1 monoclonal antibody, or other experimental drugs) of any kind are permitted while the patient is receiving study treatment.\n* Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to four weeks after the study.","90 Years",{"count":7,"type":20},[23],"This trial (molecular characterization trial) focuses on rectal cancer, a common cancer that is treated with radiotherapy (RT) as standard of care and represents a setting in which to study the effects of RT on the immune system.",[527],"Rectal Cancer",{"date":330,"type":38},{"date":530,"type":38},"2023-05-22",{"date":532,"type":20},"2028-05-31",{"name":44,"class":45},5,{"id":536,"slug":4,"hasResults":11,"nctId":537,"briefTitle":538,"officialTitle":538,"acronym":4,"eligibilityCriteria":539,"healthyVolunteers":11,"sex":268,"minAge":16,"maxAge":4,"enrollmentInfo":540,"targetDuration":4,"studyType":21,"phases":541,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":551,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":46},"100612738","NCT07257484","Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors","Inclusion Criteria:\n\n* Biologically female\n* Age ≥ 18\n* Obesity as defined by current BMI ≥ 30 kg\u002Fm²\n* Postmenopausal as defined by one or more of the following\n\n  * Age ≥60 years\n  * Age \\\u003C60 years with amenorrhea for ≥ 1 year\n  * Documented bilateral surgical oophorectomy\n  * Chemical menopause with the addition of LHRH agonists at least 12 weeks prior to enrolment, and plan to remain on LHRH agonists throughout the trial\n* HR+ (ER and\u002For PR) stage 0-III breast cancer\n* Completed curative treatment (surgery, chemotherapy, radiotherapy) at least 12 weeks prior to enrolment\n* Insurance approval for tirzepatide or willing to pay out of pocket\n* Willing to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n* Stage IV breast cancer\n* Concomitant use of CDK inhibitors\n* Concomitant use of antiHER2 therapy\n* The PI may be consulted regarding enrollment of females receiving other endocrine therapy medications\n* Other active malignancy requiring treatment\n* Enrollment in another investigational clinical trial\n* Contraindication to tirzepatide\n* Treatment with a GLP-1 receptor agonist within the last 3 months\n* Diabetes requiring insulin\n* Any disorder, unwillingness, or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the subject's safety or compliance with the protocol",{"count":483,"type":20},[58],"This study will explore whether tirzepatide is a practical and acceptable treatment for postmenopausal females with a history of hormone receptor-positive breast cancer and obesity. The investigators aim to understand whether participants are willing and able to take this medication once weekly for 6 months and whether it may help improve weight and overall health. There will be monthly check-ins to monitor progress and safety. At the beginning and end of the study, participants will undergo body composition assessments, blood tests and a stool sample will be collected, and surveys will be completed.",[544,461],"Obesity (Disorder)",[546,547,548,549],"tirzepatide","hormone receptor positive","HR+","postmenopausal","2026-06-10",{"date":376,"type":38},{"date":553,"type":38},"2026-06-08",{"date":555,"type":20},"2028-02-25",{"name":44,"class":45},{"id":558,"slug":4,"hasResults":11,"nctId":559,"briefTitle":560,"officialTitle":560,"acronym":4,"eligibilityCriteria":561,"healthyVolunteers":11,"sex":562,"minAge":16,"maxAge":364,"enrollmentInfo":563,"targetDuration":4,"studyType":21,"phases":565,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":550,"lastUpdatePostDateStruct":570,"startDateStruct":571,"completionDateStruct":573,"leadSponsor":575,"locationsCount":262},"100430585","NCT04886986","Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer","Inclusion Criteria:\n\n* Histologically or cytologically confirmed adenocarcinoma of prostate\n* Documented progressive metastatic CRPC based on Prostate Cancer Working Group 3 (PCWG3) criteria, which includes at least one of the following criteria: PSA progression, Objective radiographic progression in soft tissue, New bone lesions\n* ECOG performance status of 0-2\n* Have serum testosterone \\\u003C 50 ng\u002FdL. Subjects must continue primary androgen deprivation with an LHRH\u002FGnRH analogue (agonist\u002Fantagonist) if they have not undergone bilateral orchiectomy\n* Have previously been treated with at least one of the following: Androgen receptor signaling inhibitor (such as enzalutamide), CYP 17 inhibitor (such as abiraterone acetate)\n* Have previously received taxane chemotherapy, been determined to be ineligible for taxane chemotherapy by their physician or refused taxane chemotherapy\n* Age \\> 18 years\n* Patients must have normal organ and marrow function as defined below: Absolute neutrophil count: \\>2,000 cells\u002Fmm3, Hemoglobin: ≥9 g\u002FdL, Platelet count: \\>150,000 x 109\u002FuL, Serum creatinine: \\\u003C1.5 x upper limit of normal (ULN) or calculated creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m2 by Cockcroft-Gault, Serum total bilirubin: \\\u003C1.5 x ULN (unless due to Gilbert's syndrome in which case direct bilirubin must be normal), Serum AST and ALT: \\\u003C1.5 x ULN in the absence of liver metastases; \\\u003C3 x ULN if due to liver metastases (in both circumstances bilirubin must meet entry criteria)\n* Ability to understand, and the willingness to sign, a written informed consent document\n\nExclusion Criteria:\n\n* Implantation of investigational medical device ≤4 weeks of Treatment visit #1 (Day 1) or current enrollment in oncologic investigational drug or device study\n* Use of investigational drugs ≤4 weeks or \\\u003C5 half-lives of Treatment visit # 1(Day 1) or current enrollment in investigational oncology drug or device study\n* Prior systemic beta-emitting bone-seeking radioisotopes. Prior radium-223 is allowed provided at least 90 days have lapsed since last dose\n* For the prior PSMA-TRT-naive cohort, prior PSMA-targeted radionuclide therapy is not allowed (prior PSMA-targeted isotopes used for imaging\u002Fdiagnostic purposes are allowed, as is prior PSMA-targeted therapy that does not involve therapeutic radionuclides); For the 177Lu-PSMA small molecule exposed cohort, no dose limiting toxicity may have been observed during\u002Fafter therapy with prior treatment and all other entry criteria must be met\n* Known active brain or leptomeningeal metastases\n* History of deep vein thrombosis and\u002For pulmonary embolus within 1 month of Treatment visit #1\n* Other serious illness(es) involving the cardiac, respiratory, CNS, renal, hepatic or hematological organ systems which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study\n* Radiation therapy for treatment of PC ≤4 weeks of Treatment visit #1\n* Patients on stable dose of bisphosphonates or denosumab, which have been started no less than 4 weeks prior to treatment start, may continue on this medication, however patients are not allowed to initiate bisphosphonate\u002FDenosumab therapy during the DLT-assessment period of the study\n* Having partners of childbearing potential and not willing to use a method of birth control deemed acceptable by the principle investigator and chairperson during the study and for at least 140 days after last study drug administration\n* Currently active other malignancy other than non-melanoma skin cancer. Patients are considered not to have \"currently active\" malignancy if they have completed any necessary therapy and are considered by their physician to be at less than 30% risk of relapse\n* Known history of myelodysplastic syndrome\n* Bone scan with confluent lesions and lack of urinary tracer consistent with a \"superscan\" as determined by the investigator\n* Prior exposure to PARP inhibitor \\> 2 weeks","MALE",{"count":564,"type":20},42,[566],"PHASE1","This is a phase I dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA small molecule. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies\u002Fmolecules that recognize prostate cancer cells). This phase of the study (phase I) will determine the highest dose of the study intervention that can be safely given.",[569],"Prostate Cancer",{"date":418,"type":38},{"date":572,"type":38},"2021-06-30",{"date":574,"type":20},"2029-12",{"name":44,"class":45},{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":21,"phases":583,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":131,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":166},"100624336","NCT07408310","Trial of Spiritual Care Interventions for Patients With Cancer","1. Diagnosed with an advanced cancer.\n2. Member of a religious faith community organization.\n3. Fluent in English.\n\nExclusion Criteria:\n\n1. Received spiritual care from a healthcare chaplain within the past 2 months.\n2. Too weak or cognitively impaired to engage in study activities.",{"count":582,"type":20},288,[23],"This study aims to determine the effects of 2 spiritual care interventions. Spiritual wellness and healthcare service utilization will be measured from a sample of advanced cancer patients recruited from outpatient settings.",[586],"Advanced Cancer",[586,588],"Spiritual Care","2026-06-01",{"date":591,"type":38},"2026-06-02",{"date":593,"type":38},"2026-03-24",{"date":595,"type":20},"2029-06",{"name":44,"class":45},""]